Alloy Therapeutics announced a deal with Biogen today to help them discover antisense therapeutics using Alloy's ASO platform. Alloy Founder & CEO Errik Anderson fills us in at the company's R&D Day.
The new CEO of Stoke Therapeutics, Ian Smith, discusses Stoke Therapeutics' Dravet syndrome therapy, which caught much attention after publishing phase 1/2 data in NEJM last month
Iambic's CEO Tom Miller discusses the company's approach to AI drug discovery (hint: it's way more than protein folding), and highlights the company's clinical HER2 program, and two others on the way
Already this year Chai Discovery has raised a $130M series B and struck a discovery partnership with Eli Lilly - Co-Founder Jack Dent describes how Chai is using AI to design antibodies
CellCentric has kicked off dosing of its first registration-supporting study for the oral p300/CBP inhibitor inobrodib in multiple myeloma today
BiotechTV - News
España